Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research
C
Diagnostics & Research is Zen Rated C and is the 65th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Sentiment
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
QGEN
QIAGEN NV
$10.51B217,685,00073.65%0.00%
FONR
FONAR CORP
$107.42M6,585,97846.11%3.58%
ILMN
ILLUMINA INC
$15.60B158,300,00093.35%6.65%Net SellingNet Buying
SHC
SOTERA HEALTH CO
$3.30B283,855,07467.09%32.91%Net Selling
A
AGILENT TECHNOLOGIES INC
$34.11B284,064,72887.44%1.23%Net BuyingNet Selling
WAT
WATERS CORP
$18.10B59,509,08992.14%7.86%Net SellingNet Selling
DHR
DANAHER CORP
$141.52B715,669,59475.35%24.65%Net SellingNet Selling
RVTY
REVVITY INC
$11.61B117,869,66095.76%2.70%Net SellingNet Selling
IDXX
IDEXX LABORATORIES INC
$42.74B80,421,91791.39%1.77%Net SellingNet Selling
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$7.76B49,115,71296.73%3.27%Net BuyingNet Buying
DGX
QUEST DIAGNOSTICS INC
$18.80B111,635,47290.99%1.78%Net SellingNet Selling
MYGN
MYRIAD GENETICS INC
$481.17M92,177,38391.64%8.36%Net SellingNet Buying
FLGT
FULGENT GENETICS INC
$582.08M30,443,59553.50%42.54%Net SellingNet Selling
LH
LABCORP HOLDINGS INC
$20.91B83,700,00091.62%1.53%Net SellingNet Selling
XGN
EXAGEN INC
$127.28M18,002,41634.65%62.05%Net Selling
NTRA
NATERA INC
$21.60B136,546,58079.89%20.11%Net SellingNet Selling
MYNZ
MAINZ BIOMED NV
$4.29M2,319,35310.08%0.00%
TMO
THERMO FISHER SCIENTIFIC INC
$160.56B377,493,91287.69%0.89%Net SellingNet Selling
IQV
IQVIA HOLDINGS INC
$27.70B173,000,00052.35%47.65%Net Selling
GH
GUARDANT HEALTH INC
$6.17B123,888,04565.39%34.61%Net SellingNet Selling
EXAS
EXACT SCIENCES CORP
$10.24B188,637,67396.68%3.32%Net SellingNet Selling
MTD
METTLER TOLEDO INTERNATIONAL INC
$24.81B20,782,78695.33%4.67%Net SellingNet Buying
ACRS
ACLARIS THERAPEUTICS INC
$171.08M108,281,23958.99%41.01%Net BuyingNet Selling
NEO
NEOGENOMICS INC
$924.03M128,694,50372.29%27.71%Net BuyingNet Buying
PRE
PRENETICS GLOBAL LTD
$104.67M13,002,9758.84%0.00%
GRAL
GRAIL INC
$1.45B35,973,49466.69%26.34%Net BuyingNet Selling
CAI
CARIS LIFE SCIENCES INC
N/A283,555,1850.00%76.08%Net SellingNet Buying
PSNL
PERSONALIS INC
$571.46M88,325,13860.27%39.73%Net BuyingNet Selling
MEDP
MEDPACE HOLDINGS INC
$9.21B28,741,60927.73%72.27%Net BuyingNet Buying
CDNA
CAREDX INC
$1.11B55,680,54978.71%21.29%Net SellingNet Selling
STIM
NEURONETICS INC
$254.07M65,820,34425.85%65.61%Net BuyingNet Selling
TWST
TWIST BIOSCIENCE CORP
$2.26B59,916,14188.23%11.77%Net SellingNet Selling
ICLR
ICON PLC
$11.88B79,464,25293.12%0.00%
NDRA
ENDRA LIFE SCIENCES INC
$5.96M738,3700.11%99.89%Net Buying
SERA
SERA PROGNOSTICS INC
$103.98M37,672,78453.70%26.10%Net SellingNet Selling
NOTV
INOTIV INC
$66.30M34,352,97823.56%39.40%Net BuyingNet Selling
RDNT
RADNET INC
$4.25B75,030,09868.94%31.06%Net SellingNet Selling
APDN
APPLIED DNA SCIENCES INC
$2.27M433,1862.06%97.94%
OPK
OPKO HEALTH INC
$1.06B793,052,80323.51%76.49%Net Buying
LAB
STANDARD BIOTOOLS INC
$474.78M379,822,26854.75%45.25%Net BuyingNet Selling
NEOG
NEOGEN CORP
$1.13B217,038,26798.51%1.49%Net BuyingNet Buying
CSTL
CASTLE BIOSCIENCES INC
$563.01M28,872,31585.16%14.84%Net SellingNet Selling
DRIO
DARIOHEALTH CORP
$30.76M43,949,42416.78%38.44%Net Buying
BIAF
BIOAFFINITY TECHNOLOGIES INC
$7.82M27,249,4621.88%17.65%
CHEK
CHECK-CAP LTD
$4.61M5,851,0421.59%0.00%
VNRX
VOLITIONRX LTD
$70.57M103,022,67720.39%35.52%Net BuyingNet Selling
TRIB
TRINITY BIOTECH PLC
$13.31M359,193,4820.23%0.00%
XWEL
XWELL INC
$5.21M5,261,0241.27%98.73%Net Buying
ISPC
ISPECIMEN INC
$2.70M2,496,8580.92%99.08%
MDXH
MDXHEALTH SA
$10.84M49,497,33422.81%77.19%
PRPH
PROPHASE LABS INC
$17.66M41,541,20512.02%24.84%
PRPO
PRECIPIO INC
$22.45M1,512,0110.46%99.54%Net BuyingNet Buying
IMDX
INSIGHT MOLECULAR DIAGNOSTICS INC
$81.22M28,599,28516.42%83.58%Net Buying
STRR
STAR EQUITY HOLDINGS INC
$6.29M3,209,3400.59%99.41%Net Buying
BNR
BURNING ROCK BIOTECH LTD
$49.83M107,616,5062.04%0.00%
ADVB
ADVANCED BIOMED INC
$17.31M21,640,0000.05%0.00%
BDSX
BIODESIX INC
$45.87M146,563,03136.42%55.80%Net BuyingNet Buying

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Jul 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) is the #1 top diagnostic & research stock out of 57 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: C, Growth: B, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: B.

Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 25, which is -2 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates QGEN as a "A".

QGEN passed 10 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock return 15.5% over the past year, overperforming other diagnostic & research stocks by 35 percentage points.

Qiagen Nv has an average 1 year price target of $49.75, an upside of 3.04% from Qiagen Nv's current stock price of $48.28.

Qiagen Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Qiagen Nv, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the #2 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Fonar (NASDAQ:FONR) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Fonar (NASDAQ:FONR) has a Due Diligence Score of 39, which is 12 points higher than the diagnostic & research industry average of 27.

FONR passed 11 out of 33 due diligence checks and has average fundamentals. Fonar has seen its stock lose -2.92% over the past year, overperforming other diagnostic & research stocks by 16 percentage points.

3. Illumina (NASDAQ:ILMN)


Illumina (NASDAQ:ILMN) is the #3 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: C, Growth: A, Momentum: D, Sentiment: C, Safety: B, Financials: B, and AI: C.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 20, which is -7 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates ILMN as a "B".

ILMN passed 6 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -15.47% over the past year, overperforming other diagnostic & research stocks by 4 percentage points.

Illumina has an average 1 year price target of $109.00, an upside of 10.63% from Illumina's current stock price of $98.53.

Illumina stock has a consensus Hold recommendation according to Wall Street analysts. Of the 12 analysts covering Illumina, 25% have issued a Strong Buy rating, 16.67% have issued a Buy, 41.67% have issued a hold, while 0% have issued a Sell rating, and 16.67% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.4%, which is 1 percentage points higher than the diagnostic & research industry average of 0.65%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)


Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.86%, which is the same as the diagnostic & research industry average of 0.65%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 33% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) has an annual dividend yield of 0.61%, which is the same as the diagnostic & research industry average of 0.65%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 23.8% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -2.25% in the last day, and down -0.82% over the last week. Waters was the among the top losers in the diagnostics & research industry, dropping -13.81% yesterday.

Waters shares are trading lower after Wells Fargo downgraded the stock from Overweight to Equal-Weight and lowered its price target from $420 to $330.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 42 points higher than the diagnostic & research industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -56.13% in the past year. It has underperformed other stocks in the diagnostic & research industry by -37 percentage points.

2. Thermo Fisher Scientific (NYSE:TMO)


Thermo Fisher Scientific (NYSE:TMO) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Thermo Fisher Scientific has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Thermo Fisher Scientific's stock has dropped -21.91% in the past year. It has underperformed other stocks in the diagnostic & research industry by -3 percentage points.

3. Iqvia Holdings (NYSE:IQV)


Iqvia Holdings (NYSE:IQV) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Iqvia Holdings has a valuation score of 14, which is -1 points higher than the diagnostic & research industry average of 15. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates IQV a Valuation Rating of "B".

Iqvia Holdings's stock has dropped -29.11% in the past year. It has underperformed other stocks in the diagnostic & research industry by -10 percentage points.

Are diagnostic & research stocks a good buy now?

46.51% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 15.13% over the next year.

2.38% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 19.05% of diagnostic & research stocks are rated B (Buy), 64.29% are rated C (Hold), 14.29% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 20.04x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.